fda bpc-157 warning unapproved drug FDA's Overreach on Compounded Peptides As unapproved peptides explode in

Treatment failed in 6/176 (3%, 95% CI: 27%) patients

Inject 1-3 cm from the edge of the kneecap

What Patients Actually Report Anecdotally (and I want to underscore that word), compounding pharmacy practice sees: Reduced gut symptoms within 3 to 6 weeks for a meaningful subset of patients Improved tolerance to previously reactive foods in some cases, though this is highly variable and unpredictable Stable symptom maintenance in patients with already-controlled IBD Generally good tolerability with few reported adverse effects These are observational reports, not controlled-trial outcomes

The tb-500 peptide side effects documented in available research are generally mild and well tolerated